Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)
8.55
-0.19 (-2.17%)
Sep 10, 2026, 3:04 PM CST
SHE:002693 Revenue
Hainan Shuangcheng Pharmaceuticals had revenue of 68.72M CNY in the quarter ending June 30, 2026, with 44.83% growth. This brings the company's revenue in the last twelve months to 309.80M, up 89.55% year-over-year. In the year 2025, Hainan Shuangcheng Pharmaceuticals had annual revenue of 276.76M with 58.87% growth.
Revenue (ttm)
309.80M
Revenue Growth
+89.55%
P/S Ratio
11.70
Revenue / Employee
691.51K
Employees
448
Market Cap
3.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.76M | 102.56M | 58.87% |
| Dec 31, 2024 | 174.21M | -61.72M | -26.16% |
| Dec 31, 2023 | 235.93M | -38.82M | -14.13% |
| Jan 1, 2023 | 274.75M | -45.54M | -14.22% |
| Jan 1, 2022 | 320.29M | 50.85M | 18.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.46B |
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Harbin Medisan Pharmaceutical | 805.09M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Tibet AIM Pharm. | 684.45M |
| Shaanxi Kanghui Pharmaceutical | 429.09M |
| Lionco Pharmaceutical Group | 408.33M |